| Year |
Citation |
Score |
| 2022 |
Simoneau A, Engel JL, Bandi M, Lazarides K, Liu S, Meier SR, Choi AH, Zhang H, Shen B, Martires L, Gotur D, Pham TV, Li F, Gu L, Gong S, ... ... Wilker E, et al. Ubiquitinated PCNA drives USP1 synthetic lethality in cancer. Molecular Cancer Therapeutics. PMID 36228090 DOI: 10.1158/1535-7163.MCT-22-0409 |
0.316 |
|
| 2022 |
Shields JA, Meier SR, Bandi M, Mulkearns-Hubert EE, Hajdari N, Dam Ferdinez M, Engel JL, Silver DJ, Shen B, Zhang W, Hubert CG, Mitchell K, Shakya S, Zhao SC, Bejnood A, ... ... Wilker E, et al. VRK1 is a Synthetic Lethal Target in VRK2-deficient Glioblastoma. Cancer Research. PMID 36069976 DOI: 10.1158/0008-5472.CAN-21-4443 |
0.371 |
|
| 2021 |
DeSelm L, Huck B, Lan R, Neagu C, Potnick J, Xiao Y, Chen X, Jones R, Richardson TE, Heasley BH, Haxell T, Moore J, Tian H, Georgi K, Rohdich F, ... ... Wilker E, et al. Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers. Journal of Medicinal Chemistry. PMID 34596404 DOI: 10.1021/acs.jmedchem.1c01087 |
0.403 |
|
| 2021 |
Xiao Y, Huck BR, Lan R, DeSelm L, Chen X, Qiu H, Neagu C, Johnson T, Mochalkin I, Gardberg A, Jiang X, Tian H, Dutt V, Santos D, Head J, ... ... Wilker E, et al. Discovery of 4-Aminopyrimidine Analogs as highly Potent Dual P70S6K/Akt Inhibitors. Bioorganic & Medicinal Chemistry Letters. 128352. PMID 34481987 DOI: 10.1016/j.bmcl.2021.128352 |
0.434 |
|
| 2016 |
Machl A, Wilker EW, Tian H, Liu X, Schroeder P, Clark A, Huck BR. M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier. American Journal of Cancer Research. 6: 806-18. PMID 27186432 |
0.372 |
|
| 2011 |
Banko MR, Allen JJ, Schaffer BE, Wilker EW, Tsou P, White JL, Villén J, Wang B, Kim SR, Sakamoto K, Gygi SP, Cantley LC, Yaffe MB, Shokat KM, Brunet A. Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Molecular Cell. 44: 878-92. PMID 22137581 DOI: 10.1016/J.Molcel.2011.11.005 |
0.375 |
|
| 2008 |
Yi C, Wilker EW, Yaffe MB, Stemmer-Rachamimov A, Kissil JL. Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2 Cancer Research. 68: 7932-7937. PMID 18829550 DOI: 10.1158/0008-5472.Can-08-0866 |
0.449 |
|
| 2007 |
Lu J, Rho O, Wilker E, Beltran L, Digiovanni J. Activation of epidermal akt by diverse mouse skin tumor promoters. Molecular Cancer Research : McR. 5: 1342-52. PMID 18171992 DOI: 10.1158/1541-7786.Mcr-07-0115 |
0.533 |
|
| 2006 |
Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, Coven S, McMahon K, Kovach S, Feng Y, Yaffe MB, Jacks T, Housman D. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Research. 66: 7473-81. PMID 16885344 DOI: 10.1158/0008-5472.Can-06-1193 |
0.463 |
|
| 2005 |
Wilker E, Lu J, Rho O, Carbajal S, Beltrán L, DiGiovanni J. Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion. Molecular Carcinogenesis. 44: 137-45. PMID 16086373 DOI: 10.1002/Mc.20132 |
0.556 |
|
| 2003 |
Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Molecular Cell. 12: 841-9. PMID 14580336 DOI: 10.1016/S1097-2765(03)00382-4 |
0.421 |
|
| 1999 |
Wilker E, Bol D, Kiguchi K, Rupp T, Beltran LM, DiGiovanni J. Enhancement of susceptibility to diverse skin tumor promoters by activation of the insulin-like growth factor-1 receptor in the epidermis of transgenic mice. Molecular Carcinogenesis. 25: 122-131. PMID 10365914 DOI: 10.1002/(Sici)1098-2744(199906)25:2<122::Aid-Mc7>3.0.Co;2-8 |
0.533 |
|
| Show low-probability matches. |